Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism

Crizotinib is a standard treatment for advanced ALK‐positive non‐small‐cell lung cancer (NSCLC). We undertook this study to investigate the pharmacokinetics of crizotinib and clinical and pharmacogenomic factors that may increase the risk of adverse events (AEs). We defined clinically significant AE...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Sci
Hlavní autoři: Fujiwara, Yutaka, Hamada, Akinobu, Mizugaki, Hidenori, Aikawa, Hiroaki, Hata, Toshiyuki, Horinouchi, Hidehito, Kanda, Shintaro, Goto, Yasushi, Itahashi, Kota, Nokihara, Hiroshi, Yamamoto, Noboru, Ohe, Yuichiro
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2016
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4982581/
https://ncbi.nlm.nih.gov/pubmed/27270784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12983
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky